[1] Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, Hirata S, Nojima T, Sugiyama E, Hatta K et al: Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol 2020, 72(3):488-498. doi: 10.1002/art.41105
[2] Vojinovic T, Cavazzana I, Ceruti P, Fredi M, Modina D, Berlendis M, Franceschini F: Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. Clin Rev Allergy Immunol 2021, 60(1):87-94.doi: 10.1007/s12016-020-08814-5
[3] Sugiyama Y, Yoshimi R, Tamura M, Takeno M, Kunishita Y, Kishimoto D, Yoshioka Y, Kobayashi K, Takase-Minegishi K, Watanabe T et al: The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. Arthritis Res Ther 2018, 20(1):7. doi: 10.1186/s13075-017-1506-7
[4] Jablonski R, Bhorade S, Strek ME, Dematte J: Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease. Chest 2020, 158(1):252-263. doi: 10.1016/j.chest.2020.01.033
[5] Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, Kirino Y, Sugiyama Y, Tanino Y, Nunokawa T et al: Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease. Arthritis Rheumatol 2021, 73(4):677-686. doi: 10.1002/art.41566
[6] Li S, Sun Y, Shao C, Huang H, Wang Q, Xu K, Zhang X, Liu P, Zeng X, Xu Z: Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases. Rheumatology (Oxford) 2021, 60(3):1195-1204. doi: 10.1093/rheumatology/keaa372
[7] Barba T, Fort R, Cottin V, Provencher S, Durieu I, Jardel S, Hot A, Reynaud Q, Lega JC: Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. Autoimmun Rev 2019, 18(2):113-122. doi: 10.1016/j.autrev.2018.07.013
[8] Heukels P, Moor CC, von der Thusen JH, Wijsenbeek MS, Kool M: Inflammation and immunity in IPF pathogenesis and treatment. Respir Med 2019, 147:79-91.doi: 10.1016/j.rmed.2018.12.015
[9] Lescoat A, Lelong M, Jeljeli M, Piquet-Pellorce C, Morzadec C, Ballerie A, Jouneau S, Jego P, Vernhet L, Batteux F et al: Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol 2020, 178:114103. doi: 10.1016/j.bcp.2020.114103
[10] Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y et al: Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Arthritis Res Ther 2017, 19(1):9. doi: 10.1186/s13075-016-1214-8
[11] Rendeiro AF, Ravichandran H, Bram Y, Chandar V, Kim J, Meydan C, Park J, Foox J, Hether T, Warren S et al: The spatial landscape of lung pathology during COVID-19 progression. Nature 2021. doi: 10.1038/s41586-021-03475-6
[12] Weatherley ND, Eaden JA, Stewart NJ, Bartholmai BJ, Swift AJ, Bianchi SM, Wild JM: Experimental and quantitative imaging techniques in interstitial lung disease. Thorax 2019, 74(6):611-619. doi: 10.1136/thoraxjnl-2018-211779
[13] Peelen DM, Zwezerijnen B, Nossent EJ, Meijboom LJ, Hoekstra OS, Van der Laken CJ, Voskuyl AE: The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology (Oxford) 2020, 59(6):1407-1415. doi: 10.1093/rheumatology/kez483
[14] Ledoult E, Morelle M, Soussan M, Mekinian A, Behal H, Sobanski V, Hachulla E, Huglo D, Le Gouellec N, Remy-Jardin M et al: (18)F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. Arthritis Res Ther 2021, 23(1):76. doi: 10.1186/s13075-021-02460-8
[15] Morita Y, Kuwagata S, Kato N, Tsujimura Y, Mizutani H, Suehiro M, Isono M: 18F-FDG PET/CT useful for the early detection of rapidly progressive fatal interstitial lung disease in dermatomyositis. Intern Med 2012, 51(12):1613-1618. doi: 10.2169/internalmedicine.51.6813
[16] Li Y, Zhou Y, Wang Q: Multiple values of (18)F-FDG PET/CT in idiopathic inflammatory myopathy. Clin Rheumatol 2017, 36(10):2297-2305. doi: 10.1007/s10067-017-3794-3
[17] Motegi SI, Fujiwara C, Sekiguchi A, Hara K, Yamaguchi K, Maeno T, Higuchi T, Hirasawa H, Kodaira S, Tomonaga H et al: Clinical value of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis. J Dermatol 2019, 46(3):213-218. doi: 10.1111/1346-8138.14758
[18] Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH et al: 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017, 76(12):1955-1964. doi: 10.1136/annrheumdis-2017-211468
[19] Liang J, Xu D, Sun C, Chen W, Cao H, Lin J: Hemophagocytic Lymphohistiocytosis: Prevalence, Risk Factors, Outcome, and Outcome-related Factors in Adult Idiopathic Inflammatory Myopathies. J Rheumatol 2020, 47(10):1532-1540. doi: 10.3899/jrheum.190542
[20] Izuka S, Yamashita H, Iba A, Takahashi Y, Kaneko H: Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis. Rheumatology (Oxford) 2020. doi: 10.1093/rheumatology/keaa608
[21] Abe Y, Matsushita M, Tada K, Yamaji K, Takasaki Y, Tamura N: Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis. Rheumatology (Oxford) 2017, 56(9):1492-1497. doi: 10.1093/rheumatology/kex188
[22] Horiike Y, Suzuki Y, Fujisawa T, Yasui H, Karayama M, Hozumi H, Furuhashi K, Enomoto N, Nakamura Y, Inui N et al: Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. Rheumatology (Oxford) 2019, 58(12):2143-2152. doi: 10.1093/rheumatology/kez185
[23] Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, Enomoto N, Inui N, Nakamura Y, Hosono Y et al: Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med 2016, 121:91-99. doi: 10.1016/j.rmed.2016.10.019
[24] Kim J, Yoo SW, Kang SR, Bom HS, Song HC, Min JJ: Clinical implication of F-18 FDG PET/CT in patients with secondary hemophagocytic lymphohistiocytosis. Ann Hematol 2014, 93(4):661-667. doi: 10.1007/s00277-013-1906-y
[25] Tanaka S, Ikeda K, Uchiyama K, Iwamoto T, Sanayama Y, Okubo A, Nakagomi D, Takahashi K, Yokota M, Suto A et al: [18F]FDG uptake in proximal muscles assessed by PET/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2013, 52(7):1271-1278. doi: 10.1093/rheumatology/ket112
[26] Bronte V, Pittet MJ: The spleen in local and systemic regulation of immunity. Immunity 2013, 39(5):806-818. doi: 10.1016/j.immuni.2013.10.010
[27] Tomita M, Suzuki M, Kono Y, Nakajima K, Matsuda T, Kuge Y, Ogawa M: Influence on [(18)F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. EJNMMI Res 2020, 10(1):24. doi: 10.1186/s13550-020-0608-4
[28] Bondue B, Sherer F, Van Simaeys G, Doumont G, Egrise D, Yakoub Y, Huaux F, Parmentier M, Rorive S, Sauvage S et al: PET/CT with 18F-FDG- and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis. J Nucl Med 2015, 56(1):127-132. doi: 10.2967/jnumed.114.147421
[29] Xie N, Tan Z, Banerjee S, Cui H, Ge J, Liu RM, Bernard K, Thannickal VJ, Liu G: Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis. Am J Respir Crit Care Med 2015, 192(12):1462-1474. doi: 10.1164/rccm.201504-0780OC
[30] Savelli G, Bonacina M, Rizzo A, Zaniboni A: Activated macrophages are the main inflammatory cell in COVID-19 interstitial pneumonia infiltrates. Is it possible to show their metabolic activity and thus the grade of inflammatory burden with (18)F-Fluorocholine PET/CT? Med Hypotheses 2020, 144:109885. doi: 10.1016/j.mehy.2020.109885
[31] Chen DL, Schiebler ML, Goo JM, van Beek EJR: PET imaging approaches for inflammatory lung diseases: Current concepts and future directions. Eur J Radiol 2017, 86:371-376. doi: 10.1016/j.ejrad.2016.09.014
[32] Tanguy J, Goirand F, Bouchard A, Frenay J, Moreau M, Mothes C, Oudot A, Helbling A, Guillemin M, Bonniaud P et al: [(18)F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [(18)F]FDG PET/CT approach. Eur J Nucl Med Mol Imaging 2021. doi: 10.1007/s00259-021-05209-2
[33] Bondue B, Castiaux A, Van Simaeys G, Mathey C, Sherer F, Egrise D, Lacroix S, Huaux F, Doumont G, Goldman S: Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients. Respir Res 2019, 20(1):10. doi: 10.1186/s12931-019-0974-5
[34] Weatherley ND, Eaden JA, Stewart NJ, Bartholmai BJ, Swift AJ, Bianchi SM, Wild JM: Experimental and quantitative imaging techniques in interstitial lung disease. Thorax 2019, 74(6):611-619. doi: 10.1136/thoraxjnl-2018-211779
[35] Umeda Y, Demura Y, Morikawa M, Anzai M, Kadowaki M, Ameshima S, Tsuchida T, Tsujikawa T, Kiyono Y, Okazawa H et al: Prognostic Value of Dual-Time-Point 18F-FDG PET for Idiopathic Pulmonary Fibrosis. J Nucl Med 2015, 56(12):1869-1875. doi: 10.2967/jnumed.115.163360
[36] Akaike K, Saruwatari K, Oda S, Shiraishi S, Takahashi H, Hamada S, Iyama S, Horio Y, Tomita Y, Saeki S et al: Predictive value of (18)F-FDG PET/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy. Int J Clin Oncol 2020, 25(4):681-690. doi: 10.1007/s10147-019-01584-x
[37] Fukunaga K, Nagatani Y, Nakagawa H, Nitta-Seko A, Nagata T, Nishizono M, Kobashi K, Iguchi H, Nitta N, Hanaoka J et al: Increased (18)F-FDG accumulation in less-affected lung area in patients with non-small cell lung cancer and postoperative acute exacerbation of interstitial lung disease. Eur J Radiol 2021, 135:109477. doi: 10.1016/j.ejrad.2020.109477
[38] Yamamichi T, Shimada Y, Masuno R, Ohira T, Abe S, Yoshimura A, Ikeda N: Association between F-18 fluorodeoxyglucose uptake of noncancerous lung area and acute exacerbation of interstitial pneumonia in patients with lung cancer after resection. J Thorac Cardiovasc Surg 2020, 159(3):1111-1118 e1112. doi: 10.1016/j.jtcvs.2019.07.100
[39] Fraioli F, Lyasheva M, Porter JC, Bomanji J, Shortman RI, Endozo R, Wan S, Bertoletti L, Machado M, Ganeshan B et al: Synergistic application of pulmonary (18)F-FDG PET/HRCT and computer-based CT analysis with conventional severity measures to refine current risk stratification in idiopathic pulmonary fibrosis (IPF). Eur J Nucl Med Mol Imaging 2019, 46(10):2023-2031. doi: 10.1007/s00259-019-04386-5
[40] Adams H, Meek B, van de Garde EM, van Moorsel CH, Vugts DJ, Keijsers RG, Grutters JC: Altered splenic [(89)Zr]Zr-rituximab uptake in patients with interstitial lung disease not responding to rituximab: could this indicate a splenic immune-mediated mechanism? Am J Nucl Med Mol Imaging 2020, 10(4):168-177.
[41] Luan F, Ji Y, Peng L, Liu Q, Cao H, Yang Y, He X, Zeng N: Extraction, purification, structural characteristics and biological properties of the polysaccharides from Codonopsis pilosula: A review. Carbohydr Polym 2021, 261:117863. doi: 10.1016/j.carbpol.2021.117863
[42] Murray SG, Schmajuk G, Trupin L, Lawson E, Cascino M, Barton J, Margaretten M, Katz PP, Yelin EH, Yazdany J: A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositis. Arthritis Care Res (Hoboken) 2015, 67(5):673-680. doi: 10.1002/acr.22501
[43] Liang J, Sun C, Xu L, Xu G, Cao H, Lin J: Community-Acquired Pneumonia and Hospital-Acquired Pneumonia in Adult Patients with Idiopathic Inflammatory Myopathy: Outcome and Antibiotic Therapy. Rheumatol Ther 2021, 8(1):255-272. doi: 10.1007/s40744-020-00268-7
[44] Li Y, Gao X, Li Y, Jia X, Zhang X, Xu Y, Gan Y, Li S, Chen R, He J et al: Predictors and Mortality of Rapidly Progressive Interstitial Lung Disease in Patients With Idiopathic Inflammatory Myopathy: A Series of 474 Patients. Front Med (Lausanne) 2020, 7:363. doi: 10.3389/fmed.2020.00363
[45] Chen F, Zuo Y, Li S, Shi J, Wang G, Shu X: Clinical characteristics of dermatomyositis patients with isolated anti-Ro-52 antibody associated rapid progressive interstitial lung disease: Data from the largest single Chinese center. Respir Med 2019, 155:127-132. doi: 10.1016/j.rmed.2019.07.020